You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The company beat analyst estimates on both the top and bottom line and reported a 50 percent year over year growth in clinical testing volume in Q3.
The companies plan to develop Thermo's Oncomine Dx Target Test as a companion diagnostic for Blueprint's BLU-667 to identify RET fusions in NSCLC patients.
The company says Panorama is the only NIPT that can tell whether twins are identical or fraternal, which can impact the clinical management of a pregnancy.
Today's agreement, which covers the UK, follows distribution deals OncoDNA signed earlier this month covering Morocco and Belarus.
Diagnostics firm BioHisto Maroc will market and distribute the firm's tissue-based and liquid biopsy sequencing services to oncologists and their patients.
Advanced cancer patients at the VA will now have access to the company's blood-based PlasmaSelect 64 test as well as the CancerSelect 125 tissue test.
The coverage decision limits the test to patients with advanced lung cancers who haven't been genomically profiled and who can't receive tissue-based testing.
The lab-developed test will use Thermo Fisher Scientific's Ion sequencing platform and will be applicable to most childhood cancers.
CSO Phil Stephens said the firm is finding specific genomic alterations that appear to affect sensitivity to immunotherapies, as it also advances overall mutation burden testing.
The company believes Indian clinicians and patients will be receptive to this new technology, but only in an efficient and actionable form.